<DOC>
	<DOCNO>NCT00005637</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one chemotherapy drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combination chemotherapy follow radiation therapy treat patient malignant glioma .</brief_summary>
	<brief_title>Combination Chemotherapy Following Radiation Therapy Treating Patients With Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety efficacy extend low-dose temozolomide combine carmustine radiotherapy patient malignant glioma . - Determine maximum tolerate dose combination patient population . - Determine time progression measure baseline gadolinium-enhanced magnetic resonance imaging patient treat regimen . OUTLINE : This dose-escalation study temozolomide . Patients receive oral temozolomide daily day 1-28 carmustine IV 1-3 hour begin within 72 hour start temozolomide . Courses repeat every 8 week 1 year absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate dos temozolomide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Patients follow every 2 month . PROJECTED ACCRUAL : A total 3-24 patient accrue study within 1-2 year .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant glioma Glioblastoma Gliosarcoma Highgrade glioma Anaplastic astrocytoma Anaplastic mixed oligoastrocytoma Anaplastic oligodendroglioma Anaplastic ependymoma Must complete radiotherapy PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : More 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) SGOT/SGPT le 3 time ULN Alkaline phosphatase less 2 time ULN Renal : BUN le 1.5 time ULN Creatinine less 1.5 time ULN Pulmonary : Pulmonary function test diffusion great 50 OR Clearance pulmonary service Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No AIDSrelated illness No nonmalignant systemic disease would preclude study No acute infection require IV antibiotic No psychiatric condition would preclude study compliance No frequent vomit medical condition would interfere oral medication intake ( e.g. , partial bowel obstruction ) No prior concurrent malignancy except surgically cure carcinoma situ cervix basal cell squamous cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy No prior biologic therapy Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 2 week since prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
</DOC>